# Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease

> **NCT05042206** · PHASE1 · COMPLETED · sponsor: **Pharmicell Co., Ltd.** · enrollment: 10 (actual)

## Conditions studied

- Chronic Kidney Disease Stage 3B
- Chronic Kidney Disease stage4

## Interventions

- **BIOLOGICAL:** Cellgram-CKD

## Key facts

- **NCT ID:** NCT05042206
- **Lead sponsor:** Pharmicell Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-24
- **Primary completion:** 2023-09-21
- **Final completion:** 2023-09-21
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042206, "Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05042206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*